Cubist Systematic Strategies’s Intersect ENT, Inc XENT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-18,603
Closed -$388K 3197
2021
Q1
$388K Buy
18,603
+9,642
+108% +$223K 0.01% 2102
2020
Q4
$205K Buy
+8,961
New +$171K ﹤0.01% 2227
2020
Q1
Sell
-4,111
Closed -$102K 2583
2019
Q4
$102K Sell
4,111
-2,358
-36% -$47.8K ﹤0.01% 2186
2019
Q3
$110K Sell
6,469
-11,544
-64% -$210K ﹤0.01% 1919
2019
Q2
$410K Buy
18,013
+9,275
+106% +$250K 0.01% 1614
2019
Q1
$281K Buy
8,738
+6,053
+225% +$187K 0.01% 1551
2018
Q4
$76K Sell
2,685
-1,925
-42% -$56.4K ﹤0.01% 1807
2018
Q3
$133K Sell
4,610
-7,909
-63% -$238K 0.01% 1541
2018
Q2
$469K Buy
12,519
+9,553
+322% +$375K 0.02% 829
2018
Q1
$117K Sell
2,966
-4,317
-59% -$158K 0.01% 1564
2017
Q4
$236K Sell
7,283
-3,742
-34% -$112K 0.01% 1417
2017
Q3
$343K Buy
11,025
+2,846
+35% +$84.2K 0.02% 1068
2017
Q2
$229K Buy
+8,179
New +$185K 0.01% 1205
2016
Q4
Sell
-591
Closed -$9K 1951
2016
Q3
$9K Buy
+591
New +$8.9K ﹤0.01% 1642
2016
Q1
Sell
-928
Closed -$21K 1910
2015
Q4
$21K Sell
928
-3,965
-81% -$78.4K ﹤0.01% 1682
2015
Q3
$114K Buy
4,893
+2,228
+84% +$61.5K 0.01% 1604
2015
Q2
$76K Buy
+2,665
New +$69.8K ﹤0.01% 1658
2014
Q4
Sell
-12,881
Closed -$200K 2100
2014
Q3
$200K Buy
+12,881
New +$194K 0.01% 1375

Other funds holding XENT

Cubist Systematic Strategies's XENT Position: Q2 2021 in Review

Cubist Systematic Strategies sold out of Intersect ENT, Inc (XENT) in Q2 2021, closing a stake of 18,603 shares — an estimated $388K sold.

Cubist Systematic Strategies first reported a position in XENT in Q3 2014 and held it in 18 quarters. The position peaked at $469K in Q2 2018. 107 funds tracked by Wall St. Rank hold XENT as of Q2 2021.

  • Cubist Systematic Strategies reported no remaining Intersect ENT, Inc position as of Q2 2021 after selling out during the quarter.
  • Cubist Systematic Strategies sold 18,603 Intersect ENT, Inc shares in Q2 2021, an estimated $388K.
  • Cubist Systematic Strategies first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 18 quarters.
  • Cubist Systematic Strategies's Intersect ENT, Inc position peaked at $469K in Q2 2018.
  • 107 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2021.

Based on Cubist Systematic Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.